China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
You may also be interested in...
Scholz Visit Paves Way For Limited China BioNTech Vaccine Use
Recent visits by foreign dignitaries and progress with local mRNA vaccines and antivirals appear to be helping some slight relaxations in China's strict COVID policies, but some experts predict it may still take months for further steps.
ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets
Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.
Chinese Public Payer Data Show More New Drugs Get Faster Coverage
China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.